On August 20, 2020 Medivir AB reported that Interim Result January – June 2020 (Press release, Medivir, AUG 20, 2020, View Source;interim-report-january—june-2020-301115445.html [SID1234563883])
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
April – June
Significant events during the quarter
Following the positive opinion given by the European Medicines Agency (EMA), the European Commission granted orphan medicinal product designation in the EU for MIV-818 for the treatment of patients with hepatocellular carcinoma (HCC), the most common type of primary liver cancer.
The Board of Directors appointed Yilmaz Mahshid as the new CEO of Medivir. Yilmaz Mahshid has long and broad experience from qualified roles in the life science sector. He will assume his position on September 14, 2020.
The U.S. Food and Drug Administration (FDA) granted orphan drug designation to MIV-818 for the treatment of patients with hepatocellular carcinoma (HCC).
Financial summary for the quarter
Net turnover amounted to SEK 4.0 (3.7) million.
The loss before interest, tax, depreciation and amortization (EBITDA) amounted to SEK -12.4 (-12.5) million. Basic and diluted earnings per share amounted to SEK -0.52 (-0.51) and SEK -0.52 (-0.51) respectively.
Cash flow from operating activities amounted to SEK -23.3 (-35.5) million.
Liquid assets and short-term investments at the end of the period amounted to SEK 94.9 (191.9) million
January – June
Financial summary
Net turnover amounted to SEK 11.4 (5.7) million.
The loss before interest, tax, depreciation and amortization (EBITDA) amounted to SEK -33.1 (-66.6) million. Basic and diluted earnings per share amounted to SEK -1.49 (-2.81) and SEK -1.49 (-2.81) respectively.
Cash flow from operating activities amounted to SEK -40.0 (-91.8) million.
Liquid assets and short-term investments at the end of the period amounted to SEK 94.9 (191.9) million.
Significant events after the end of the quarter
In July, a research collaboration was initiated with the Drug Discovery and Development Platform (DDD) at SciLifeLab on potential inhibitors of SARS CoV-2. Through the collaboration, DDD will get access to Medivir’s unique proprietary protease-targeted compound library.
Conference call for investors, analysts and the media
The Interim Report January – June 2020 will be presented by Medivir’s President & CEO, Uli Hacksell.
Time: Thursday, August 20, 2020, at 14.00 (CET).
The conference call will also be streamed via a link on the website: www.medivir.com
The presentation will be available on Medivir’s website after completion of the conference.